anti-PD-L1 antibody and anti-PD-1 antibody (Quartett)



Quartett’s website is here

anti-PD-L1 Rabbit Monoclonals -Successfully tested in national and international studies and ring trials

Over the last years the research of Programmed Death Ligand 1 (PD-L1, also known as CD274 or B7-H1) became more attractive because of a potential role in cancer therapy. The 40 kDa transmembrane protein binds to the receptor Programmed death-1 (PD-1), which is a T cell immune checkpoint. The activation of the pathway leads to an inhibition of the T cell activation to avoid an autoimmune response. Several tumor cell and tumor-infiltrating immune cells exploit this mechanism to evade destruction and to be resistant to CD8+ T cellmediated lysis.

Human tonsil stained with anti-PD-L1 (QR1)

quartett offers with PD-L1 (clone QR1) a new monoclonal rabbit antibody that is reactive in formalin-fixed paraffin-embedded human tissues. The antibody is a predictive marker of different cancer types, including sentinel lymph node melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and triple negative breast cancer cells (TNBC) where it provides a membranous and cytoplasmic staining.

Product information

Code Name Format Volume Instruction
1-PR292-02 PD-L1 (QR1) concentrate 100 μl acrobat_reader_50x50
1-PR292-05 PD-L1 (QR1) concentrate 500 μl
1-PR292-07 PD-L1 (QR1) concentrate 1 ml
2-PR292-07 PD-L1 (QR1) ready-to-use 1 ml
2-PR292-10 PD-L1 (QR1) ready-to-use 3 ml
2-PR292-13 PD-L1 (QR1) ready-to-use 7 ml


anti-PD-1 Rabbit Monoclonals -New marker for human PD-1

Programmed Death 1 (PD-1, CD279) is a transmembrane protein functioning as surface receptor for its ligands PD-L1 and PD-L2. PD-1 is expressed mainly on activated T-cells, B-cells and myeloid cells. PD-1 is an immune checkpoint and plays a crucial role in down regulation of the immune system through inhibition of T-cell activation, which in turn reduces autoimmunity. Some tumor cells use this mechanism to prevent apoptosis by inhibiting T-cells directed to them.

PD-1 (QR2) is a useful marker for angioimmunoblastic lymphoma. Furthermore, increased expression of PD-1 has been found to be associated with poor prognosis in hepatocellular carcinoma and renal cell carcinoma.

Treatments targeting PD-1 have shown encouraging results in breast cancer, non-small cell lung cancer (NSCLC) and melanoma.

Human lymph node stained with anti-PD-1 (QR2)

Product information

Code Name Format Volume Instruction
1-PR294-02 PD-1 (QR2) concentrate 100 μl In Preparation
1-PR294-05 PD-1 (QR2) concentrate 500 μl
1-PR294-07 PD-1 (QR2) concentrate 1 ml
2-PR294-07 PD-1 (QR2) ready-to-use 1 ml
2-PR294-10 PD-1 (QR2) ready-to-use 3 ml
2-PR294-13 PD-1 (QR2) ready-to-use 7 ml

Please contact us for any inquiries, questions, or information requests.
Tokyo Future Style, Inc.
TEL:029-851-9222 FAX:029-851-9220